Rotigotine transdermal delivery for the treatment of restless legs syndrome

Bibliography

• Allen RP, Picchietti D, Hening WA, Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4(2):101-19
   PubMed Web of Science ®Google Scholar
• Berger K, Luedemann J, Trenkwalder C, Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164(2):196-202
   PubMedGoogle Scholar
• Picchietti MA, Picchietti DL. Restless legs syndrome and periodic limb movement disorder in children and adolescents. Semin Pediatr Neurol 2008;15(2):91-9
   PubMedGoogle Scholar
• Walters AS, Hickey K, Maltzman J, A questionnaire study of 138 patients with restless legs syndrome: the ‘Night-Walkers’ survey. Neurology 1996;46(1):92-5
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006;7(7):545-52
   PubMedGoogle Scholar
• Winkelmann J, Polo O, Provini F, Genetics of restless legs syndrome (RLS): state-of-the-art and future directions. Mov Disord 2007;22(Suppl 18):S449-58
   Google Scholar
• Winkelmann J, Wetter TC, Collado-Seidel V, Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 360 patients. Sleep 2000;23(5):597-602
   Google Scholar
• Trenkwalder C, Hogl B, Winkelmann J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol 2009;256(4):539-53
   PubMedGoogle Scholar
• Winkelmann J, Schormair B, Lichtner P, Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39(8):1000-6
   PubMedGoogle Scholar
• Barriere G, Cazalets JR, Bioulac B, The restless legs syndrome. Prog Neurobiol 2005;77(3):139-65
   PubMedGoogle Scholar
• Stiasny-Kolster K, Kohnen R, Moller JC, Validation of the ‘L-DOPA test’ for diagnosis of restless legs syndrome. Mov Disord 2006;21(9):1333-9
   PubMedGoogle Scholar
• Chesson AL Jr, Anderson WM, Littner M, Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999;22(8):1128-33
   PubMedGoogle Scholar
• Littner MR, Kushida C, Anderson WM, Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27(3):557-9
   PubMedGoogle Scholar
• Vignatelli L, Billiard M, Clarenbach P, EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006;13(10):1049-65
   PubMedGoogle Scholar
• Oertel WH, Trenkwalder C, Zucconi M, State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007;22 (Suppl 18):S466-75
   Google Scholar
• Trenkwalder C, Hening WA, Montagna P, Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23(16):2267-302
   PubMedGoogle Scholar
• Zanettini R, Antonini A, Gatto G, Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356(1):39-46
   PubMedGoogle Scholar
• Trenkwalder C, Benes H, Poewe W, Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7(7):595-604
   PubMedGoogle Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9(3):228-39
   PubMedGoogle Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008;9(8):865-73
   PubMedGoogle Scholar
• Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005;65(2 Suppl 1):S3-5
   Google Scholar
• Belluzzi JD, Domino EF, May JM, N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9(2):147-54
   PubMedGoogle Scholar
• Kehr J, Hu XJ, Goiny M, Scheller DK. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007;114(8):1027-31
   PubMedGoogle Scholar
• Swart PJ, De Zeeuw RA. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 1992;47(8):613-5
   PubMedGoogle Scholar
• Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005;65(2 Suppl 1):S6-10
   PubMedGoogle Scholar
• Reynolds NA, Wellington K, Easthope SE. Rotigotine: in Parkinson's disease. CNS Drugs 2005;19(11):973-81
   PubMedGoogle Scholar
• Baldwin CM, Keating GM. Rotigotine transdermal patch: in restless legs syndrome. CNS Drugs 2008;22(10):797-806
   PubMedGoogle Scholar
• Neupro® transdermal patch. Package Label. Available from: http://www.emea.eiropa.eu.humandocs/PDFs/EPAR/ neupro/H-626-PI-en.pdf. 2009
   Google Scholar
• Hansen K, Braun M, Horstmann R. Low drug drug interaction potential of rotigotine. J Clin Pharmacol 2005;45 (abstract):1091
   Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009;10(4):677-91
   PubMedGoogle Scholar
• EMEA European Medicines Agency Press release Doc.Ref.EMEA/CHMP/322964/2009. Available from: http://www.emea.europa.eu. 2009
   Google Scholar
• Stiasny-Kolster K, Kohnen R, Schollmayer E, Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19(12):1432-8
   PubMedGoogle Scholar
• Trenkwalder C, Stiasny-Kolster K, Garcia-Borreguero D, Rotigotine transdermal patch provides higher responder rates in patients with restless legs syndrome: 24 month results from a multi-national, multi-centre, open-label follow-up trial [abstract no. 901]. Mov Disord 2007;22 (Suppl 16):275, S74
   PubMedGoogle Scholar
• Trenkwalder C, Garcia-Borreguero D, Poewe W, Improvements over 24 months in patients with moderate to severe idiopathic restless legs syndrome treated with a rotigotine transdermal patch: results from a multi-national, multi-centre, open-label follow-up trial. Neurology 2007;68(Suppl):P06.001
   Google Scholar
• Hoegl B, Trenkwalder C, Stiasny-Kolster K, Rotigotine transdermal patch improves quality of life in patients with restless legs syndrome: 24 month results from a multi-national, multi-centre, open-label follow-up trial. Eur J Neurol 2007;14(Suppl 1):14
   Google Scholar
• Garcia-Borreguero D, Poewe W, Hoegl B, Long-term safety and efficacy of rotigotine in idiopathic RLS: 3-year results from a multinational open-label trial. Mov Disord 2008;23(Suppl 1):S367
   Google Scholar
• Hening W, Allen R, Becker P, The rotigotine transdermal patch Is effective in the treatment of idiopathic RLS: results from a 6-month, multicenter, double-blind, placebo-controlled trial. [abstract No 1121 plus poster]. 12th International Congress of the Movement Disorder Society, 22-26 Jun 2008; Chicago (IL), USA
   Google Scholar
• Oertel WM, Benes H, Ferini-Strambi L, Assessment of rotigotine in idiopathic RLS: results of a 7-week sleep lab trial. Mov Disord 2008;23(Suppl 1):S370
   Google Scholar
• Oertel W, Benes H, Garcia-Borreguero D, Rotigotine transdermal patch in idiopathic restless legs syndrome — a randomized, placebo-controlled polysomnographic study. Sleep Med 2010 [In press]
   Google Scholar
• Walters AS, LeBrocq C, Dhar A, Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4(2):121-32
   PubMed Web of Science ®Google Scholar
• Kohnen R, Oertel WH, Stiasny-Kolster K, Severity rating of restless legs syndrome: validation of the RLS-6 Scales. Sleep 2004;27:A304
   Google Scholar
• Garcia-Borreguero D, Ferini-Strambi L, Kohnen R. Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials. Eur J Neurol 2008;15(Suppl 3):110
   Google Scholar
• Benes H, Garcia-Borreguero D, Allen R, Kohnen R. Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine–a retrospective systematic analysis of two large open-label 1-year trials. Mov Disord 2009;24(Suppl 1):S438
   Google Scholar
• Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19(3):205-13
   PubMedGoogle Scholar
• Garcia-Borreguero D, Allen RP, Kohnen R, Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8(5):520-30
   PubMedGoogle Scholar
• Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006;5(10):878-86
   PubMedGoogle Scholar
• Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008;9(5):572-4
   PubMedGoogle Scholar
• Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26(7):819-21
   PubMedGoogle Scholar
• Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5(1):9-14
   PubMedGoogle Scholar
• Garcia-Borreguero D, Kohnen R, Hogl B, Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007;8(5):455-63
   PubMedGoogle Scholar
• Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64(8):1089-96
   PubMedGoogle Scholar
• Tippmann-Peikert M, Park JG, Boeve BF, Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68(4):301-3
   PubMedGoogle Scholar